ModuleTitle@CompanyName@Symbol@Address@Phone@Industry@Sector@Region@CompanyDescription@KeyExecutives
Company Description@Seattle Genetics, Inc.@SGEN@21823 30TH DRIVE SE SUITE, BOTHELL, Washington, 98021, United States of America@4255274000@Biotechnology: Biological Products (No Diagnostic Substances)@Health Care@North America@"Seattle Genetics is a biotechnology company that develops and commercializes
therapies targeting cancer. We are commercializing ADCETRISÂ®, or brentuximab
vedotin, for the trbreatment of certain CD30-expressing lymphomas, and PADCEVTM,
or enfortumab vedotin-ejfv, for the treatment of certain metastatic urothelial
cancers. We are also advancing a pipeline of novel therapies for solid tumors
and blood-related cancers designed to address unmet medical needs and improve
treatment outcomes for patients. Many of our programs, including ADCETRIS and
PADCEV, are based on our antibody-drug conjugate, or ADC, technology that
utilizes the targeting ability of monoclonal antibodies to deliver cell-killing
agents directly to cancer cells.
ADCETRIS is commercially available in more than 70 countries worldwide. We
commercialize ADCETRIS in the U.S.&nbsp;&nbsp;... <a href=""http://secfilings.nasdaq.com/edgar_conv_html%2f2020%2f02%2f06%2f0001060736-20-000006.html#FIS_BUSINESS"" target=""_blank"">More</a> ...&nbsp;&nbsp;
"@[('Clay B. Siegall', 'Chairman, President & Chief Executive Officer'), ('Robert J. Lechleider', 'Senior Vice President-Clinical Development'), ('Roger D. Dansey', 'Chief Medical Officer'), ('Todd E. Simpson', 'Chief Financial Officer'), ('Vaughn B. Himes', 'Chief Technical Officer')]
